Dana-Farber Cancer Institute
Boston, MA
Accepting patients
AZTOUND
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
- DNMT1 Inhibitor
- Phase 2/3
- Has results
Accepting patients
IS-free Treg Stem Cell Transplant
A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory AML/MDS
- Allogeneic Stem Cell Transplant
- Phase 1
- Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
- Phase 1
Accepting patients
AG-120
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- IDH1 Inhibitor
- Phase 1
Accepting patients
CROSSCHECK-001
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias (CROSSCHECK-001)
- T Cell Engager (TCE)
- Cathepsin G (CTSG)
- Phase 1
Accepting patients
Eganelisib
A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- PI3K Inhibitor
- Randomization
- Phase 1
Accepting patients
MGD024
A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies
- Bispecific Antibody
- Phase 1
Not currently accepting
TakeAim
TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination With Azacitidine or Venetoclax
- Hypomethylating Agents (HMA)
- IRAK 4 Inhibitor
- BCL-2 Inhibitor
- Phase 1/2
- Has results
Not yet accepting
Naïve T Cell Depletion
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- Allogeneic Stem Cell Transplant
- Pre-Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
LP-118
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory NHL, RT, MM, T-PLL, Acute Leukemia (AML, ALL), MDS, MDS/MPN, and MF
- Bcl/xL Inhibitor
- BCL-2 Inhibitor
- Phase 1